US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.36 against a street estimate of 0.30 — a beat of 20.0%.
Analysts rate Ironwood Pharmaceuticals Inc a buy (2 buy, 2 hold, 0 sell out of 4) with an average price target of $6.10.
| Fund | Stake |
|---|---|
| BlackRock Inc | 10.77% |
| Armistice Capital, LLC | 8.43% |
| Sarissa Capital Management LP | 5.56% |
| State Street Corp | 5.33% |
| Bank of America Corp | 5.26% |
| Renaissance Technologies Corp | 4.84% |
| Vanguard Capital Management, LLC | 4.00% |
| AQR Capital Management LLC | 3.91% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • For the quarter ended September 30, 2026, revenue was $133,040 thousand, compared with $122,060 thousand in the same quarter of 20 | 2026-11-05 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 total revenue was $133.0 million, up from $122.1 million in Q3 2025. • GAAP net income was $59.8 million, or $0.36 per ba | 2026-11-05 |
| Board / officer change · Q4 2026 HEADLINE NUMBERS • Ironwood Pharmaceuticals announced a planned CEO transition. • Tammi Gaskins, currently Senior Vice President and Chief Commercia | 2026-10-16 |
| Quarterly report · Q2 2026 IRONWOOD PHARMACEUTICALS, INC. — Q2 2026 SUMMARY HEADLINE NUMBERS • Collaborative arrangements revenue (six months): $219,547 thousand (vs. $126,382 | 2026-08-06 |
| Results announced · Q3 2026 IRONWOOD PHARMACEUTICALS - Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 total revenue: $113.0 million (up 33% vs Q2 2025: $85.2 million) • Q2 | 2026-08-06 |
| Board / officer change · Q2 2026 IRONWOOD PHARMACEUTICALS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting of Stockholders held June 16, 2026 • 10,000,000 additional share | 2026-06-18 |
| Company announcement · Q2 2026 IRONWOOD PHARMACEUTICALS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • $200.0 million convertible senior notes repaid in full on June 15, 2026 at sche | 2026-06-15 |
| Board / officer change · Q2 2026 IRONWOOD PHARMACEUTICALS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • No financial results or revenue figures disclosed in this filing • Document dat | 2026-05-13 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ironwood Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.